Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Three Strikes But Not Out: GSK Maneuvers Through A Third R&D Setback

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline’s decision to end a Phase III trial testing the cancer immunotherapy MAGE-A3 in NSCLC is no surprise, following disappointing results in two trials, but coupled with other disappointing R&D news it put more pressure on the company to deliver on its respiratory launches.

You may also be interested in...



Avastin Ovarian Cancer Approval Brings Some Clarity On PFS Endpoint

New claim for platinum-resistant recurrent disease based on a median 3.4-month improvement in progression-free survival – with favorable trends in overall survival, overall response rate and duration of response – confirms agency’s willingness to entertain a progression endpoint in this tumor type.

Post-Novartis, GSK Assures Immuno-Oncology R&D Running At Full Speed

Working with partners, GSK aims to have at least two new cancer immunotherapies in the clinic by mid-2015, says Axel Hoos, the former BMS exec who developed the checkpoint grandfather Yervoy.

Post-Novartis, GSK Assures Immuno-Oncology R&D Running At Full Speed

Working with partners, GSK aims to have at least two new cancer immunotherapies in the clinic by mid-2015, says Axel Hoos, the former BMS exec who developed the checkpoint grandfather Yervoy.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel